Interject 15% Injection

Country: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

Oxytetracycline hydrochloride

Disponibbli minn:

Interchem Ireland Ltd

Kodiċi ATC:

QJ01AA06

INN (Isem Internazzjonali):

Oxytetracycline hydrochloride

Dożaġġ:

15 percent weight/volume

Għamla farmaċewtika:

Solution for injection

Tip ta 'preskrizzjoni:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupp terapewtiku:

Cattle, Pigs, Sheep

Żona terapewtika:

oxytetracycline

Indikazzjonijiet terapewtiċi:

Antibacterial

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2008-03-21

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Interject 15% Injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE
Oxytetracycline Hydrochloride Ph. Eur.
150 mg
EXCIPIENTS
Dimethylacetamide
q.s to
1 ml (Approx. 48 %)
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solution for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, sheep and pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_Interject 15%_ is recommended in the treatment of a wide range of
common systemic, respiratory and local infections
caused by, or associated with, organisms sensitive to Oxytetracycline.
4.3 CONTRAINDICATIONS
Do not use in sheep producing milk for human consumption.
Do not use in animals with known hypersensitivity to the active
ingredient.
Do not administer intravenously.
Do not use in horses, dogs and cats.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
Wash hands after use. This product contains dimethylacetamide (DMAC)
and care should be taken to prevent absorption
through the skin.
Use of the product should be based on susceptibility testing of the
bacteria isolated from the animal.
If this is not
possible, therapy should be based on local (regional, farm level)
epidemiological information about susceptibility of the
target bacteria.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_